Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics

Biswas, Tithi; Jindal, Charulata; Fitzgerald, Timothy L.; Efird, Jimmy T.

doi:10.3390/ijerph16010124

Cited by 26 publications

(30 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This improved survival was observed for all subtypes, but especially for HER2+ tumor subtypes. In the present study, the pCR rates in all IBC patients were considerably higher (23.2%) than previously reported in population-based analyses [ 9 , 21 ]. The HR+/HER2+ and HR−/HER2+ subtypes displayed the highest pCR rates.…”

Section: Discussioncontrasting

confidence: 81%

See 1 more Smart Citation

Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer

Uden

Maaren

Bult³

et al. 2019

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose To analyze the influence of hormone receptors (HR) and Human Epidermal growth factor Receptor-2 (HER2)-based molecular subtypes in stage III inflammatory breast cancer (IBC) on tumor characteristics, treatment, pathologic response to neoadjuvant chemotherapy (NACT), and overall survival (OS). Methods Patients with stage III IBC, diagnosed in the Netherlands between 2006 and 2015, were classified into four breast cancer subtypes: HR+/HER2− , HR+/HER2+ , HR−/HER2+ , and HR−/HER2−. Patient-, tumor-and treatment-related characteristics were compared. In case of NACT, pathologic complete response (pCR) was compared between subgroups. OS of the subtypes was compared using Kaplan-Meier curves and the log-rank test. Results 1061 patients with stage III IBC were grouped into subtypes: HR+/HER2− (N = 453, 42.7%), HR−/HER2− (N = 258, 24.3%), HR−/HER2+ (N = 180,17.0%), and HR+/HER2+ (N = 170,16.0%). In total, 679 patients (85.0%) received NACT. In HR−/HER2+ tumors, pCR rate was highest (43%, (p < 0.001). In case of pCR, an improved survival was observed for all subtypes, especially for HR+/HER2+ and HR−/HER2+ tumor subtypes. Trimodality therapy (NACT, surgery, radiotherapy) improved 5-year OS as opposed to patients not receiving this regimen: HR+/HER2− (74.9 vs. 46.1%), HR+/HER2+ (80.4 vs. 52.6%), HR−/HER2+ (76.4 vs. 29.7%), HR−/HER2− (47.6 vs. 27.8%). Conclusions In stage III IBC, breast cancer subtypes based on the HR and HER2 receptor are important prognostic factors of response to NACT and OS. Patients with HR−/HER2− IBC were less likely to achieve pCR and had the worst OS, irrespective of receiving most optimal treatment regimen to date (trimodality therapy).

show abstract

Section: Discussioncontrasting

confidence: 81%

“…The HR+/HER2+ and HR−/HER2+ subtypes displayed the highest pCR rates. Likely this reflects the use of HER2-targeted therapies, which was more often applied in our study than in previous studies in case of HER2-positive disease [ 9 , 21 ].…”

Section: Discussionmentioning

confidence: 51%

Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer

Uden

Maaren

Bult³

et al. 2019

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Moreover, pCR subjects were more likely to obtain a prolonged overall survival in the current findings, which is consistent with previous research findings [39,40]. e PLD and epirubicin groups still obtained similar treatment effects in both univariate and multivariate regression analysis after a matched case-control design, which demonstrates the warranted efficacy of PLD for breast cancer in neoadjuvant settings.…”

Section: Resultssupporting

confidence: 92%

The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan

Hung

Yang

Tsai

et al. 2020

Biochemistry Research International

View full text Add to dashboard Cite

Breast cancer is a global issue regarding women’s health, and high incident rates remain in the Taiwanese female population. Chemotherapy, using anthracycline-based chemotherapeutic agents in neoadjuvant settings, has been introduced as a promising new therapeutic option for treatment of invasive breast cancer. Set apart from conventional anthracycline regimens such as epirubicin, pegylated liposomal doxorubicin (Lipo-Dox®, PLD) was introduced for providing a justifiable treatment effect, while offering a favorable toxicity profile for breast cancer patients in a metastatic setting. However, the efficacy of PLD in neoadjuvant settings for breast cancer patients has not yet been sufficiently reported. This study aims to investigate the efficacy of PLD-based neoadjuvant chemotherapy in breast cancer patients using a retrospective matched case-control study. A total of 183 PLD cases and 183 epirubicin-based controls were included after a 1 : 1 ratio case-control matching procedure was held, according to the matching criteria. These criteria included the patient’s preoperative clinical stage, molecular subtype, chemotherapy regimen with taxanes prior to surgery, and histological grade. All data were collected according to an institutional review board approved protocol. The study results reported that the PLD and epirubicin groups both obtained similar outcomes in pathologic complete response (pCR), recurrence, and overall survival rate with no statistically significant differences. Overall, the study results demonstrate that PLD-based neoadjuvant chemotherapy offers a similar effect of treatment with a favorable toxicity profile within the study follow-up duration, when compared with conventional epirubicin-based neoadjuvant chemotherapy.

show abstract

“…Other studies also conclude that tumor dimension is an important factor of the outcome in IBC. 17 Consistent with the findings of numerous other authors, this study has determined that the number of months of survival increased significantly in cases that had an N0 stage compared to N1 cases and above. 18,19 Only two (7.40%) patients in this study had distant metastases, a lower percentage than that found in a study performed in the US, in which about 36% of patients with IBC had metastases at diagnosis.…”

Section: Figuresupporting

confidence: 92%

<p>Survival Analysis of Patients with Inflammatory Breast Cancer in Relation to Clinical and Histopathological Characteristics</p>

Preda

Ilina

Potre

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose: To evaluate the survival of patients with inflammatory breast cancer (IBC) and to correlate these survival rates with the histopathological parameters found in the resection specimen of the tumor. Patients and Methods: This retrospective study was based on 27 patients that had been diagnosed and had undergone surgery in the 2nd General and Oncological Surgery Clinic of the County Emergency Hospital in Timisoara, Romania. Data about the patient group were collected from archived patient files over a period of eight years starting from January 2008. The collected data regarded age, tumor size and histopathological type and immunohistochemistry (IHC), presence or absence of tumor embolus in lymphatic or blood vessels and the presence or absence of distant metastases at the time of diagnosis. We evaluated the impact of tumor characteristics on the patients' outcome. Results: The 12-month survival rates postsurgery were significantly increased if tumors were <5 cm compared to those >5 cm (p=0.046), if nodal status was N0 vs N1-2 (p=0.039), as well as in cases where distant metastases were absent, compared to patients with distant metastases (p=0.001, α=0.001) and positive-hormone receptors (p=0.043). Survival was influenced neither by histopathological type (p=0.357) nor by the presence of tumor embolus in the resection specimen (p=0.250) and HER2 status (p=0.763). Survival at 12 months after surgery was equal between those with stage IIIB noninflammatory breast cancer (NIBC) and IBC. At 24 months after surgery, IBC cases presented a significantly lower probability of survival. Conclusion: The prognosis of patients with IBC is reserved compared to NIBC, increased tumor size, positive lymph node, hormone receptors negative cases and distant metastases drastically decreasing survival rates.

show abstract

Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics

Cited by 26 publications

References 67 publications

Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer

Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer

The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan

<p>Survival Analysis of Patients with Inflammatory Breast Cancer in Relation to Clinical and Histopathological Characteristics</p>

Contact Info

Product

Resources

About